Acute heart failure (AHF) continues to have unacceptably high rates of mortality and morbidity. This position paper highlights the need for more intense interdisciplinary cooperation as one key element to overcome the challenges associated with fragmentation in the care of AHF patients. Additional aspects discussed include the importance of early diagnosis and treatment, options for initial treatment, referral bias as a potential cause for treatment preferences among experts, considerable uncertainty regarding patient disposition, the diagnosis of accompanying acute myocardial infarction, the need for antibiotic therapy, as well as assessment of intravascular volume status.
paper aims to complement current guidelines 1, 2 and other important recent efforts to highlight unmet needs in AHF. This position paper does not address cardiogenic shock or imaging, as they have been addressed elsewhere. 6, 7 The aim of this position paper is to highlight several key insights that lead to the formation of the AHF study group, including fragmentation in the care of AHF patients and the wide spectrum of AHF phenotypes and systemic triggers, as well as the need for early diagnosis and treatment. As a key conceptual approach to AHF patients aimed to tackle these challenging issues, we want to initiate a call for interdisciplinary care.
Fragmentation in care
Multiple physicians and multiple specialties are involved in the care of AHF patients (Figure 1 ), including general practitioners, emergency physicians, cardiologists, hospitalists, internists, geriatricians and intensivists, as well as nurses, paramedics, case managers and physiotherapists. Patient pathways differ substantially from country to country as well as within countries. Moreover, in contrast to the care of patients with acute myocardial infarction (AMI), the roles and responsibilities of these different specialties regarding AHF are not well defined in many hospitals. Our call for interdisciplinary care aims to alert all physicians to the requirement for collaboration of all clinicians involved in AHF to optimise the management of this complex condition. Each medical craft group covers only a part of the patient journey in their institution, and without a patient-focused whole-of-care approach, optimal outcomes cannot be produced. Recognising this fact should help accepting the necessity for close cooperation and interaction with the other specialists involved. The chosen model for the multidisciplinary team and the care pathways need to be carefully selected according to the resources and experience available at a local hospital level. Once an integrated care pathway is developed with all parties having agreed on a set of assessment and therapy standards and aims, the dissemination of appropriate supporting tools (such as protocols, standard order sets and pocket guides) and institutionalised feedback will ensure consistency of care across the disciplines. [1] [2] [3] [4] [5] 
Insights gained from interactive case discussions
In addition, this position paper will highlight and discuss insights gained during two meetings evolving from interdisciplinary discussions of management issue of individual patient scenarios that were presented from different AHF experts (Supplementary Material, Cases 1 to 6). These interactive and educational cases (real cases!) are an integral part of this position paper and were selected to highlight and quantify by voting among experts major discrepancies and uncertainties regarding basic management decision for common AHF scenarios. Discrepancies in specific management decisions among experts to large extent are due to lack of solid evidence. Highlighting and quantifying discrepancies and uncertainties among experts will be used to identify the areas of most urgent need for more evidence and hence drive future efforts in clinical research. When trying to solve the cases, you are asked for your clinical decisions and you will see the voting obtained during the meetings.
Referral bias may explain treatment preferences
The interdisciplinary discussion among experts created novel insights that highlighted discrepancies due to substantial referral bias, one important cause of differences in clinical practice. Cardiologists with particular expertise in the care of patients with advanced and chronic heart failure see predominately patients with different AHF phenotypes as compared to emergency physicians, internists or cardiologists working in the emergency department (ED). The former treat predominately AHF resulting from a gradual deterioration of chronic heart failure that is accompanied often with substantial weight gain and accumulation of peripheral oedema. Not surprisingly, loop diuretics are considered the first line therapy of AHF by these experts. In contrast, emergency physicians, internists, or cardiologists working in the ED also see a substantial number of patients with rapid development of acute cardiogenic pulmonary oedema. These patients often have little or no peripheral oedema, often with preserved systolic left ventricular ejection fraction, present with elevated blood pressure and seem to suffer predominately from 'vascular failure'. Again, not surprisingly, these experts consider vasodilators, particularly nitrates, as the first line therapy of AHF. 14, 15 
Early diagnosis of AHF
Acute dyspnoea is the key symptom of most AHF patients. As acute dyspnoea has a broad differential diagnosis including pneumonia, exacerbated obstructive pulmonary disease and pulmonary embolus, early and accurate diagnosis can be challenging, particularly in patients with a history of both cardiac and obstructive pulmonary disease (Supplementary Material, Case 1). Delays establishing the correct diagnosis and appropriate treatment may influence subsequent length of hospital stay, morbidity and mortality. 10, 16, 17 The diagnostic process includes three steps. First, ensuring that AHF is the cause of acute dyspnoea. This first step relies on clinical judgment to integrate patient history, physical examination (particularly elevated neck veins, peripheral oedema, and bilateral basal pulmonary rales), investigations including chest x-ray findings of cardiomegaly and congestion, the 12-lead electrocardiogram (ECG), as well as elevated levels of natriuretic peptides. 1, 2, 17 In the ED, as well as the primary care setting, measurement of natriuretic peptides has been demonstrated to be extremely helpful in the diagnosis/exclusion of AHF and to support treatment and referral decisions. 1, 2, [17] [18] [19] [20] [21] Cardiac imaging with echocardiography is key in the second step in order to define the underlying cardiac pathology. If natriuretic peptides are available and in the absence of shock, echocardiography can usually be deferred to the second day.
Step three in the diagnostic process starts in the ED and aims to establish the trigger of AHF, as this will offer additional treatment options, e.g. antibiotics for sepsis. For an efficient diagnostic process, it is also critical that there is consensus among the different healthcare providers regarding the diagnostic tests and criteria adopted in their specific facility.
Disposition
Fortunately, only a small minority of AHF patients present in shock or with severe respiratory failure. [1] [2] [3] [4] [5] [6] [7] [8] Whilst there is broad consensus that these very sick patients should be treated in an intensive care unit, there is considerable uncertainty regarding the appropriate disposition of the remaining 90% of AHF patients (Supplementary Material, Case 1 and Case 2). This uncertainty is in stark contrast to the established concept and consensus of treating patients with AMI within the first 24 h (or longer) in a coronary care unit. In most institutions, patients with AHF currently complete their initial diagnostic assessment and therapeutic intervention in the ED (Figure 2 ).
Diagnosis of accompanying AMI
The challenges surrounding the diagnosis of AMI in the presence of AHF are illustrated in the Supplementary Material, Case 2 and Case 4. This dilemma has huge clinical implications as coronary artery disease is the cardiac pathology underlying AHF in more than 50% of patients. [1] [2] [3] [4] [5] [6] In order to trigger AHF, in the absence of arrhythmia or acute mitral regurgitation, AMI usually has to jeopardise a large amount of myocardium. This can most easily be identified and quantified in patients presenting with ST-segment elevation myocardial infarction and in patients with substantial elevations in cardiac troponin (e.g. more than 100 times the 99 th percentile). [21] [22] [23] In the absence of studies with the appropriate methodology to determine the presence/absence of AMI in unselected AHF patients, the true incidence of AMI or unstable angina in patients with AHF is unknown. An assumption is that as a general rule, in the absence of ECG changes indicative of a large area of myocardial ischaemia such as ST-segment elevation, new left bundle brunch block, ST-segment elevation in aVR, or ST-segment depression in several precordial leads, patients with a clinical diagnosis of AHF, usually do not require early coronary angiography. They do not have a sufficiently high likelihood of clinical benefit from early coronary angiography and if indicated early revascularisation. 23, 24 Based on the criteria suggested in the recent ESC guidelines on myocardial revscularisation, 24 coronary angiography and revascularisation may well be indicated after initial stabilisation of AHF on an elective basis.
Early treatment of AHF
The primary goal of initial treatment is the improvement of acute dyspnoea and the reduction in intracardiac filling pressures, the subjective and objective hallmarks of the AHF syndrome. 1, 2, 6 There is increasing evidence that 'early' treatment may beneficially influence clinical outcomes for patients with AHF. 1, 2, 6, 11, [14] [15] [16] Initiation of a high-dose intravenous nitrates immediately after presentation in patients with cardiogenic pulmonary oedema reduced the rate of AHF patients requiring mechanical ventilation and reduced adverse endpoints. 14 Early initiation of non-invasive positive pressure ventilation improved dyspnoea and respiratory distress. 25 In the ADHERE registry, early (⩽6 h) compared with late (6-48 h) initiation of vasoactive treatment (median time 1.7 vs 14.7 h) was associated with significantly lower mortality rates (p<0.0001) in patients hospitalised with AHF. 11 Moreover, a 48 h infusion of serelaxin early after presentation of AHF patients, was associated with reduced mortality after six months of follow-up (Supplementary Material, Case 1, Case 3 and Case 4). 25 Of major interest, immediate treatment for AHF in the ED may mediate organ protection. 26, 27 Circulating cardiac troponin levels, an indicator of cardiomyocyte injury, increase early during the decompensation episode in patients with AHF. [26] [27] [28] [29] [30] As release of biomarkers of organ damage and dysfunction are associated with worse outcomes in patients with AHF, this suggests that early treatment may be beneficial in modulating the underlying pathophysiological processes, thereby minimising organ damage and dysfunction. [26] [27] [28] [29] [30] The concept of early treatment also applies to factors identified as triggers of AHF, such as sepsis due to pneumonia. The auscultatory and radiographic features of congestion and pneumonia overlap substantially and have suboptimal sensitivity. Thus, body temperature as well as biomarkers of bacterial infection including C-reactive protein and procalcitonin deserve particular attention (Supplementary Material, Case 2). 31, 32 
Assessment of intravascular volume status
Intravascular volume is increased in the majority of untreated AHF patients. 1, 2 Physical examination can provide important clues in the initial assessment, as well as the response to treatment. In contrast to common belief, the accuracy of most clinicians in estimating and interpreting intravascular volume status seems to be suboptimal. 1, 2 Reasons include less focus on basic physical examination in the medical education, inability to visualise neck veins in certain physiognomies, practical difficulties (such as positioning and non-invasive assisted ventilation) in assessment in the severely unwell patient, as well as discrepancies between arterial and venous filling (Supplementary Material, Case 5 and Case 6). 31, [33] [34] [35] Errors in estimating intravascular status may easily lead to incorrect treatment decisions, however, the diagnosis of reduced intravascular volume can be challenging. Beyond careful clinical examination with a focus on the filling of neck veins in different positions, blood pressure and heart rate in the resting as well as in the standing position (which is not possible in the most severely unwell), serial measurements of serum creatinine and blood urea nitrogen during the treatment of AHF patients are the standard of care. A rising pattern after the initiation of intensive diuretic therapy usually indicates pre-renal renal dysfunction due to arterial underfilling. Similarly, excessive intravascular volume is difficult to determine. Natriuretic peptides have emerged as simple non-invasive tools that can be used to complement clinical assessment (neck veins) and sonography (diameter and response to inspiration of the vena cava inferior) in the quantification of intracardiac filling pressures in AHF. [33] [34] [35] 
Conclusions
This position paper strongly endorses intense interdisciplinary cooperation as a key element to overcome at least some of the immense challenges in the care of AHF patients. Acknowledging our uncertainty, and sometimes even ignorance, regarding key aspects of care with honesty should help to join forces in both research as well as clinical care. Beyond indicating areas of uncertainty, this review also highlights emerging concepts with which they can be potentially overcome.
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